The global market for Diabetic Gastroparesis was estimated to be worth US$ 2093.8 million in 2023 and is forecast to a readjusted size of US$ 3010.2 million by 2030 with a CAGR of 5.4% during the forecast period 2024-2030

Diabetic Gastroparesis - Market

Diabetes type 1 and type 2 are one of the most common chronic diseases prevalent in the world, affecting millions of people. One of the disorders associated with diabetes type 1 and type 2 is gastroparesis, which is characterized by the delayed emptying of the stomach. One of the major causes of gastroparesis is damage to the vagus nerve, reducing the mobility of the stomach contents. Diabetic neuropathy affects the vagus nerve, in cases where the blood glucose levels remain high over a longer duration. Diabetes gastroparesis is usually diagnosed with the help of imaging techniques such as ultrasound and x-ray, which is accompanied by the intake of radio isotopic meals containing barium, or using hematological / blood tests, and endoscopic techniques. There has been a marked increase in the prevalence of diabetes, especially in the developing countries, including China, India, Brazil, and some other Asian countries, leading to increasing incidence of diabetic neuropathy and consequent rise in diabetes gastroparesis around the world.

According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines.

Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Diabetic Gastroparesis, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Diabetic Gastroparesis by region & country, by Type, and by Application.

The Diabetic Gastroparesis market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Diabetic Gastroparesis.

Market Segmentation

Scope of Diabetic Gastroparesis - Market Report

Report Metric	Details
Report Name	Diabetic Gastroparesis - Market
Forecasted market size in 2030	US$ 3010.2 million
CAGR	5.4%
Forecasted years	2024 - 2030
Segment by Type:	Drugs Surgical Treatment Products
Segment by Application	Hospital Pharmacies Retail Pharmacies Online Pharmacies
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Medtronic, Sumitomo Dainippon Pharma, Abbott Laboratories, Boston Scientific Corporation, C. R. Bard, Inc, Janssen Global Services, LLC, Alfasigma SpA, Evoke Pharma, Cadila Pharmaceuticals, Sanofi, Teva Pharmaceutical Industries Ltd, Pfizer, Vanda Pharmaceuticals, Allergan
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Diabetic Gastroparesis manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Diabetic Gastroparesis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Diabetic Gastroparesis in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Diabetic Gastroparesis - Market size in 2030?

Ans: The Diabetic Gastroparesis - Market size in 2030 will be US$ 3010.2 million.

Who are the main players in the Diabetic Gastroparesis - Market report?

Ans: The main players in the Diabetic Gastroparesis - Market are Medtronic, Sumitomo Dainippon Pharma, Abbott Laboratories, Boston Scientific Corporation, C. R. Bard, Inc, Janssen Global Services, LLC, Alfasigma SpA, Evoke Pharma, Cadila Pharmaceuticals, Sanofi, Teva Pharmaceutical Industries Ltd, Pfizer, Vanda Pharmaceuticals, Allergan

What are the Application segmentation covered in the Diabetic Gastroparesis - Market report?

Ans: The Applications covered in the Diabetic Gastroparesis - Market report are Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What are the Type segmentation covered in the Diabetic Gastroparesis - Market report?

Ans: The Types covered in the Diabetic Gastroparesis - Market report are Drugs, Surgical Treatment Products

1 Market Overview

1.1 Diabetic Gastroparesis Product Introduction

1.2 Global Diabetic Gastroparesis Market Size Forecast

1.3 Diabetic Gastroparesis Market Trends & Drivers

1.3.1 Diabetic Gastroparesis Industry Trends

1.3.2 Diabetic Gastroparesis Market Drivers & Opportunity

1.3.3 Diabetic Gastroparesis Market Challenges

1.3.4 Diabetic Gastroparesis Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Diabetic Gastroparesis Players Revenue Ranking (2023)

2.2 Global Diabetic Gastroparesis Revenue by Company (2019-2024)

2.3 Key Companies Diabetic Gastroparesis Manufacturing Base Distribution and Headquarters

2.4 Key Companies Diabetic Gastroparesis Product Offered

2.5 Key Companies Time to Begin Mass Production of Diabetic Gastroparesis

2.6 Diabetic Gastroparesis Market Competitive Analysis

2.6.1 Diabetic Gastroparesis Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Diabetic Gastroparesis Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Diabetic Gastroparesis as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Drugs

3.1.2 Surgical Treatment Products

3.2 Global Diabetic Gastroparesis Sales Value by Type

3.2.1 Global Diabetic Gastroparesis Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Diabetic Gastroparesis Sales Value, by Type (2019-2030)

3.2.3 Global Diabetic Gastroparesis Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospital Pharmacies

4.1.2 Retail Pharmacies

4.1.3 Online Pharmacies

4.2 Global Diabetic Gastroparesis Sales Value by Application

4.2.1 Global Diabetic Gastroparesis Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Diabetic Gastroparesis Sales Value, by Application (2019-2030)

4.2.3 Global Diabetic Gastroparesis Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Diabetic Gastroparesis Sales Value by Region

5.1.1 Global Diabetic Gastroparesis Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Diabetic Gastroparesis Sales Value by Region (2019-2024)

5.1.3 Global Diabetic Gastroparesis Sales Value by Region (2025-2030)

5.1.4 Global Diabetic Gastroparesis Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Diabetic Gastroparesis Sales Value, 2019-2030

5.2.2 North America Diabetic Gastroparesis Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Diabetic Gastroparesis Sales Value, 2019-2030

5.3.2 Europe Diabetic Gastroparesis Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Diabetic Gastroparesis Sales Value, 2019-2030

5.4.2 Asia Pacific Diabetic Gastroparesis Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Diabetic Gastroparesis Sales Value, 2019-2030

5.5.2 South America Diabetic Gastroparesis Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Diabetic Gastroparesis Sales Value, 2019-2030

5.6.2 Middle East & Africa Diabetic Gastroparesis Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Diabetic Gastroparesis Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Diabetic Gastroparesis Sales Value

6.3 United States

6.3.1 United States Diabetic Gastroparesis Sales Value, 2019-2030

6.3.2 United States Diabetic Gastroparesis Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Diabetic Gastroparesis Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Diabetic Gastroparesis Sales Value, 2019-2030

6.4.2 Europe Diabetic Gastroparesis Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Diabetic Gastroparesis Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Diabetic Gastroparesis Sales Value, 2019-2030

6.5.2 China Diabetic Gastroparesis Sales Value by Type (%), 2023 VS 2030

6.5.3 China Diabetic Gastroparesis Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Diabetic Gastroparesis Sales Value, 2019-2030

6.6.2 Japan Diabetic Gastroparesis Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Diabetic Gastroparesis Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Diabetic Gastroparesis Sales Value, 2019-2030

6.7.2 South Korea Diabetic Gastroparesis Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Diabetic Gastroparesis Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Diabetic Gastroparesis Sales Value, 2019-2030

6.8.2 Southeast Asia Diabetic Gastroparesis Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Diabetic Gastroparesis Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Diabetic Gastroparesis Sales Value, 2019-2030

6.9.2 India Diabetic Gastroparesis Sales Value by Type (%), 2023 VS 2030

6.9.3 India Diabetic Gastroparesis Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Medtronic

7.1.1 Medtronic Profile

7.1.2 Medtronic Main Business

7.1.3 Medtronic Diabetic Gastroparesis Products, Services and Solutions

7.1.4 Medtronic Diabetic Gastroparesis Revenue (US$ Million) & (2019-2024)

7.1.5 Medtronic Recent Developments

7.2 Sumitomo Dainippon Pharma

7.2.1 Sumitomo Dainippon Pharma Profile

7.2.2 Sumitomo Dainippon Pharma Main Business

7.2.3 Sumitomo Dainippon Pharma Diabetic Gastroparesis Products, Services and Solutions

7.2.4 Sumitomo Dainippon Pharma Diabetic Gastroparesis Revenue (US$ Million) & (2019-2024)

7.2.5 Sumitomo Dainippon Pharma Recent Developments

7.3 Abbott Laboratories

7.3.1 Abbott Laboratories Profile

7.3.2 Abbott Laboratories Main Business

7.3.3 Abbott Laboratories Diabetic Gastroparesis Products, Services and Solutions

7.3.4 Abbott Laboratories Diabetic Gastroparesis Revenue (US$ Million) & (2019-2024)

7.3.5 Boston Scientific Corporation Recent Developments

7.4 Boston Scientific Corporation

7.4.1 Boston Scientific Corporation Profile

7.4.2 Boston Scientific Corporation Main Business

7.4.3 Boston Scientific Corporation Diabetic Gastroparesis Products, Services and Solutions

7.4.4 Boston Scientific Corporation Diabetic Gastroparesis Revenue (US$ Million) & (2019-2024)

7.4.5 Boston Scientific Corporation Recent Developments

7.5 C. R. Bard, Inc

7.5.1 C. R. Bard, Inc Profile

7.5.2 C. R. Bard, Inc Main Business

7.5.3 C. R. Bard, Inc Diabetic Gastroparesis Products, Services and Solutions

7.5.4 C. R. Bard, Inc Diabetic Gastroparesis Revenue (US$ Million) & (2019-2024)

7.5.5 C. R. Bard, Inc Recent Developments

7.6 Janssen Global Services, LLC

7.6.1 Janssen Global Services, LLC Profile

7.6.2 Janssen Global Services, LLC Main Business

7.6.3 Janssen Global Services, LLC Diabetic Gastroparesis Products, Services and Solutions

7.6.4 Janssen Global Services, LLC Diabetic Gastroparesis Revenue (US$ Million) & (2019-2024)

7.6.5 Janssen Global Services, LLC Recent Developments

7.7 Alfasigma SpA

7.7.1 Alfasigma SpA Profile

7.7.2 Alfasigma SpA Main Business

7.7.3 Alfasigma SpA Diabetic Gastroparesis Products, Services and Solutions

7.7.4 Alfasigma SpA Diabetic Gastroparesis Revenue (US$ Million) & (2019-2024)

7.7.5 Alfasigma SpA Recent Developments

7.8 Evoke Pharma

7.8.1 Evoke Pharma Profile

7.8.2 Evoke Pharma Main Business

7.8.3 Evoke Pharma Diabetic Gastroparesis Products, Services and Solutions

7.8.4 Evoke Pharma Diabetic Gastroparesis Revenue (US$ Million) & (2019-2024)

7.8.5 Evoke Pharma Recent Developments

7.9 Cadila Pharmaceuticals

7.9.1 Cadila Pharmaceuticals Profile

7.9.2 Cadila Pharmaceuticals Main Business

7.9.3 Cadila Pharmaceuticals Diabetic Gastroparesis Products, Services and Solutions

7.9.4 Cadila Pharmaceuticals Diabetic Gastroparesis Revenue (US$ Million) & (2019-2024)

7.9.5 Cadila Pharmaceuticals Recent Developments

7.10 Sanofi

7.10.1 Sanofi Profile

7.10.2 Sanofi Main Business

7.10.3 Sanofi Diabetic Gastroparesis Products, Services and Solutions

7.10.4 Sanofi Diabetic Gastroparesis Revenue (US$ Million) & (2019-2024)

7.10.5 Sanofi Recent Developments

7.11 Teva Pharmaceutical Industries Ltd

7.11.1 Teva Pharmaceutical Industries Ltd Profile

7.11.2 Teva Pharmaceutical Industries Ltd Main Business

7.11.3 Teva Pharmaceutical Industries Ltd Diabetic Gastroparesis Products, Services and Solutions

7.11.4 Teva Pharmaceutical Industries Ltd Diabetic Gastroparesis Revenue (US$ Million) & (2019-2024)

7.11.5 Teva Pharmaceutical Industries Ltd Recent Developments

7.12 Pfizer

7.12.1 Pfizer Profile

7.12.2 Pfizer Main Business

7.12.3 Pfizer Diabetic Gastroparesis Products, Services and Solutions

7.12.4 Pfizer Diabetic Gastroparesis Revenue (US$ Million) & (2019-2024)

7.12.5 Pfizer Recent Developments

7.13 Vanda Pharmaceuticals

7.13.1 Vanda Pharmaceuticals Profile

7.13.2 Vanda Pharmaceuticals Main Business

7.13.3 Vanda Pharmaceuticals Diabetic Gastroparesis Products, Services and Solutions

7.13.4 Vanda Pharmaceuticals Diabetic Gastroparesis Revenue (US$ Million) & (2019-2024)

7.13.5 Vanda Pharmaceuticals Recent Developments

7.14 Allergan

7.14.1 Allergan Profile

7.14.2 Allergan Main Business

7.14.3 Allergan Diabetic Gastroparesis Products, Services and Solutions

7.14.4 Allergan Diabetic Gastroparesis Revenue (US$ Million) & (2019-2024)

7.14.5 Allergan Recent Developments

8 Industry Chain Analysis

8.1 Diabetic Gastroparesis Industrial Chain

8.2 Diabetic Gastroparesis Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Diabetic Gastroparesis Sales Model

8.5.2 Sales Channel

8.5.3 Diabetic Gastroparesis Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Medtronic Inc

Sumitomo Dainippon Pharma

Abbott Laboratories

Boston Scientific Corporation

C R Bard Inc

Janssen Global Services, LLC

Evoke Pharma

Cadila Pharmaceuticals

Sanofi

Teva Pharmaceutical Industries Ltd

Pfizer Inc

Vanda Pharmaceuticals

Allergan plc

Alfasigma SpA

List of Tables

Table 1. Diabetic Gastroparesis Market Trends

Table 2. Diabetic Gastroparesis Market Drivers & Opportunity

Table 3. Diabetic Gastroparesis Market Challenges

Table 4. Diabetic Gastroparesis Market Restraints

Table 5. Global Diabetic Gastroparesis Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Diabetic Gastroparesis Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Diabetic Gastroparesis Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Diabetic Gastroparesis Product Type

Table 9. Key Companies Time to Begin Mass Production of Diabetic Gastroparesis

Table 10. Global Diabetic Gastroparesis Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Diabetic Gastroparesis as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Diabetic Gastroparesis Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Diabetic Gastroparesis Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Diabetic Gastroparesis Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Diabetic Gastroparesis Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Diabetic Gastroparesis Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Diabetic Gastroparesis Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Diabetic Gastroparesis Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Diabetic Gastroparesis Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Diabetic Gastroparesis Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Diabetic Gastroparesis Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Diabetic Gastroparesis Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Diabetic Gastroparesis Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Diabetic Gastroparesis Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Diabetic Gastroparesis Sales Value by Region (2019-2024) & (%)

Table 27. Global Diabetic Gastroparesis Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Diabetic Gastroparesis Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Diabetic Gastroparesis Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Diabetic Gastroparesis Sales Value, (2025-2030) & (US$ Million)

Table 31. Medtronic Basic Information List

Table 32. Medtronic Description and Business Overview

Table 33. Medtronic Diabetic Gastroparesis Products, Services and Solutions

Table 34. Revenue (US$ Million) in Diabetic Gastroparesis Business of Medtronic (2019-2024)

Table 35. Medtronic Recent Developments

Table 36. Sumitomo Dainippon Pharma Basic Information List

Table 37. Sumitomo Dainippon Pharma Description and Business Overview

Table 38. Sumitomo Dainippon Pharma Diabetic Gastroparesis Products, Services and Solutions

Table 39. Revenue (US$ Million) in Diabetic Gastroparesis Business of Sumitomo Dainippon Pharma (2019-2024)

Table 40. Sumitomo Dainippon Pharma Recent Developments

Table 41. Abbott Laboratories Basic Information List

Table 42. Abbott Laboratories Description and Business Overview

Table 43. Abbott Laboratories Diabetic Gastroparesis Products, Services and Solutions

Table 44. Revenue (US$ Million) in Diabetic Gastroparesis Business of Abbott Laboratories (2019-2024)

Table 45. Abbott Laboratories Recent Developments

Table 46. Boston Scientific Corporation Basic Information List

Table 47. Boston Scientific Corporation Description and Business Overview

Table 48. Boston Scientific Corporation Diabetic Gastroparesis Products, Services and Solutions

Table 49. Revenue (US$ Million) in Diabetic Gastroparesis Business of Boston Scientific Corporation (2019-2024)

Table 50. Boston Scientific Corporation Recent Developments

Table 51. C. R. Bard, Inc Basic Information List

Table 52. C. R. Bard, Inc Description and Business Overview

Table 53. C. R. Bard, Inc Diabetic Gastroparesis Products, Services and Solutions

Table 54. Revenue (US$ Million) in Diabetic Gastroparesis Business of C. R. Bard, Inc (2019-2024)

Table 55. C. R. Bard, Inc Recent Developments

Table 56. Janssen Global Services, LLC Basic Information List

Table 57. Janssen Global Services, LLC Description and Business Overview

Table 58. Janssen Global Services, LLC Diabetic Gastroparesis Products, Services and Solutions

Table 59. Revenue (US$ Million) in Diabetic Gastroparesis Business of Janssen Global Services, LLC (2019-2024)

Table 60. Janssen Global Services, LLC Recent Developments

Table 61. Alfasigma SpA Basic Information List

Table 62. Alfasigma SpA Description and Business Overview

Table 63. Alfasigma SpA Diabetic Gastroparesis Products, Services and Solutions

Table 64. Revenue (US$ Million) in Diabetic Gastroparesis Business of Alfasigma SpA (2019-2024)

Table 65. Alfasigma SpA Recent Developments

Table 66. Evoke Pharma Basic Information List

Table 67. Evoke Pharma Description and Business Overview

Table 68. Evoke Pharma Diabetic Gastroparesis Products, Services and Solutions

Table 69. Revenue (US$ Million) in Diabetic Gastroparesis Business of Evoke Pharma (2019-2024)

Table 70. Evoke Pharma Recent Developments

Table 71. Cadila Pharmaceuticals Basic Information List

Table 72. Cadila Pharmaceuticals Description and Business Overview

Table 73. Cadila Pharmaceuticals Diabetic Gastroparesis Products, Services and Solutions

Table 74. Revenue (US$ Million) in Diabetic Gastroparesis Business of Cadila Pharmaceuticals (2019-2024)

Table 75. Cadila Pharmaceuticals Recent Developments

Table 76. Sanofi Basic Information List

Table 77. Sanofi Description and Business Overview

Table 78. Sanofi Diabetic Gastroparesis Products, Services and Solutions

Table 79. Revenue (US$ Million) in Diabetic Gastroparesis Business of Sanofi (2019-2024)

Table 80. Sanofi Recent Developments

Table 81. Teva Pharmaceutical Industries Ltd Basic Information List

Table 82. Teva Pharmaceutical Industries Ltd Description and Business Overview

Table 83. Teva Pharmaceutical Industries Ltd Diabetic Gastroparesis Products, Services and Solutions

Table 84. Revenue (US$ Million) in Diabetic Gastroparesis Business of Teva Pharmaceutical Industries Ltd (2019-2024)

Table 85. Teva Pharmaceutical Industries Ltd Recent Developments

Table 86. Pfizer Basic Information List

Table 87. Pfizer Description and Business Overview

Table 88. Pfizer Diabetic Gastroparesis Products, Services and Solutions

Table 89. Revenue (US$ Million) in Diabetic Gastroparesis Business of Pfizer (2019-2024)

Table 90. Pfizer Recent Developments

Table 91. Vanda Pharmaceuticals Basic Information List

Table 92. Vanda Pharmaceuticals Description and Business Overview

Table 93. Vanda Pharmaceuticals Diabetic Gastroparesis Products, Services and Solutions

Table 94. Revenue (US$ Million) in Diabetic Gastroparesis Business of Vanda Pharmaceuticals (2019-2024)

Table 95. Vanda Pharmaceuticals Recent Developments

Table 96. Allergan Basic Information List

Table 97. Allergan Description and Business Overview

Table 98. Allergan Diabetic Gastroparesis Products, Services and Solutions

Table 99. Revenue (US$ Million) in Diabetic Gastroparesis Business of Allergan (2019-2024)

Table 100. Allergan Recent Developments

Table 101. Key Raw Materials Lists

Table 102. Raw Materials Key Suppliers Lists

Table 103. Diabetic Gastroparesis Downstream Customers

Table 104. Diabetic Gastroparesis Distributors List

Table 105. Research Programs/Design for This Report

Table 106. Key Data Information from Secondary Sources

Table 107. Key Data Information from Primary Sources

Table 108. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Diabetic Gastroparesis Product Picture

Figure 2. Global Diabetic Gastroparesis Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Diabetic Gastroparesis Sales Value (2019-2030) & (US$ Million)

Figure 4. Diabetic Gastroparesis Report Years Considered

Figure 5. Global Diabetic Gastroparesis Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Diabetic Gastroparesis Revenue in 2023

Figure 7. Diabetic Gastroparesis Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Drugs Picture

Figure 9. Surgical Treatment Products Picture

Figure 10. Global Diabetic Gastroparesis Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 11. Global Diabetic Gastroparesis Sales Value Market Share by Type, 2023 & 2030

Figure 12. Product Picture of Hospital Pharmacies

Figure 13. Product Picture of Retail Pharmacies

Figure 14. Product Picture of Online Pharmacies

Figure 15. Global Diabetic Gastroparesis Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 16. Global Diabetic Gastroparesis Sales Value Market Share by Application, 2023 & 2030

Figure 17. North America Diabetic Gastroparesis Sales Value (2019-2030) & (US$ Million)

Figure 18. North America Diabetic Gastroparesis Sales Value by Country (%), 2023 VS 2030

Figure 19. Europe Diabetic Gastroparesis Sales Value (2019-2030) & (US$ Million)

Figure 20. Europe Diabetic Gastroparesis Sales Value by Country (%), 2023 VS 2030

Figure 21. Asia Pacific Diabetic Gastroparesis Sales Value (2019-2030) & (US$ Million)

Figure 22. Asia Pacific Diabetic Gastroparesis Sales Value by Country (%), 2023 VS 2030

Figure 23. South America Diabetic Gastroparesis Sales Value (2019-2030) & (US$ Million)

Figure 24. South America Diabetic Gastroparesis Sales Value by Country (%), 2023 VS 2030

Figure 25. Middle East & Africa Diabetic Gastroparesis Sales Value (2019-2030) & (US$ Million)

Figure 26. Middle East & Africa Diabetic Gastroparesis Sales Value by Country (%), 2023 VS 2030

Figure 27. Key Countries/Regions Diabetic Gastroparesis Sales Value (%), (2019-2030)

Figure 28. United States Diabetic Gastroparesis Sales Value, (2019-2030) & (US$ Million)

Figure 29. United States Diabetic Gastroparesis Sales Value by Type (%), 2023 VS 2030

Figure 30. United States Diabetic Gastroparesis Sales Value by Application (%), 2023 VS 2030

Figure 31. Europe Diabetic Gastroparesis Sales Value, (2019-2030) & (US$ Million)

Figure 32. Europe Diabetic Gastroparesis Sales Value by Type (%), 2023 VS 2030

Figure 33. Europe Diabetic Gastroparesis Sales Value by Application (%), 2023 VS 2030

Figure 34. China Diabetic Gastroparesis Sales Value, (2019-2030) & (US$ Million)

Figure 35. China Diabetic Gastroparesis Sales Value by Type (%), 2023 VS 2030

Figure 36. China Diabetic Gastroparesis Sales Value by Application (%), 2023 VS 2030

Figure 37. Japan Diabetic Gastroparesis Sales Value, (2019-2030) & (US$ Million)

Figure 38. Japan Diabetic Gastroparesis Sales Value by Type (%), 2023 VS 2030

Figure 39. Japan Diabetic Gastroparesis Sales Value by Application (%), 2023 VS 2030

Figure 40. South Korea Diabetic Gastroparesis Sales Value, (2019-2030) & (US$ Million)

Figure 41. South Korea Diabetic Gastroparesis Sales Value by Type (%), 2023 VS 2030

Figure 42. South Korea Diabetic Gastroparesis Sales Value by Application (%), 2023 VS 2030

Figure 43. Southeast Asia Diabetic Gastroparesis Sales Value, (2019-2030) & (US$ Million)

Figure 44. Southeast Asia Diabetic Gastroparesis Sales Value by Type (%), 2023 VS 2030

Figure 45. Southeast Asia Diabetic Gastroparesis Sales Value by Application (%), 2023 VS 2030

Figure 46. India Diabetic Gastroparesis Sales Value, (2019-2030) & (US$ Million)

Figure 47. India Diabetic Gastroparesis Sales Value by Type (%), 2023 VS 2030

Figure 48. India Diabetic Gastroparesis Sales Value by Application (%), 2023 VS 2030

Figure 49. Diabetic Gastroparesis Industrial Chain

Figure 50. Diabetic Gastroparesis Manufacturing Cost Structure

Figure 51. Channels of Distribution (Direct Sales, and Distribution)

Figure 52. Bottom-up and Top-down Approaches for This Report

Figure 53. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions